Research

A WMRA podcast alludes to UVA's role in the biotechnology industry in Central Virginia.

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

NSF funding will allow UVA Engineering’s Link Lab to develop a new program that will train graduate students to make discoveries and then translate that knowledge into new technologies, products and services.

Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.

A WMRA podcast alludes to UVA's role in the biotechnology industry in Central Virginia.

Insulin delivery technology developed at UVA and commercialized by TypeZero Technologies, Inc. received initial support from UVA's Licensing and Ventures Group (LVG).

The UVA Licensing & Ventures Group (LVG) has invested in three Charlottesville-based ventures that grew out of University research. TypeZero Technologies Inc., TearSolutions Inc., and Mission Secure Inc.

Professor Gregory B. Fairchild is the first director of Northern Virginia operations for the University of Virginia.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

Plans are underway to create ease of connection between UVA's Research Park, CHO, and the Hollymead Town Center to benefit Virginia visitors and businesses.

The University has approved an academic affiliation with INOVA Health System and George Mason University.